

SYGNIS Pharma AG

Corporate Overview

SYGNIS Pharma AG is a European biopharmaceutical company listed on the Prime Standard of the German Stock Exchange (LIOK; ISIN: DE000A1E9B74). Headquartered in Heidelberg, SYGNIS is focused on the development of novel therapies for the treatment of Central Nervous System (CNS) disorders including acute stroke and various forms of dementia.

SYGNIS is supported by a number of high-profile shareholders, who have a significant interest in the sustained development of the Company. In addition, by signing a Standby Equity Distribution Agreement in October 2009 SYGNIS secured access to up to €10 million, which it has the right to draw down in tranches over three years.

Product portfolio and therapeutic focus

SYGNIS' product pipeline currently focuses on its preclinical KIBRA-Project as well as on its compound, AX200, which is currently undergoing a multinational phase II efficacy trial for the treatment of acute stroke. When AX200 is administered during acute stroke, the drug supports the body's natural protection process, helping to prevent cell death (thus reducing infarct size) and stimulating the generation of new nerve cells and blood vessels. In addition, the compound supports the regeneration of neuronal networks, stimulating nerve cells to form new connections with other nerve cells. As a result, the patient's quality of life will be improved.

By acquisition of the US-based Amnestix, SYGNIS has entered new avenues to develop novel therapeutics for the treatment of age-related memory deficiency, Alzheimer's disease and other neurological diseases. In 2010, SYGNIS achieved proof of concept in preclinical in vivo studies that the modulation of the KIBRA pathway affects cognitive functions and improves working memory.

Corporate Strategy

SYGNIS is working intensively on the expansion of its product pipeline through the addition of drug candidates that are mitigating the risk profile of the company. SYGNIS' strategy for growth includes the development of new products from its own research and through in-licensing and acquisitions.

Management Board

Peter Willinger, CFO

Dr. Frank Rathgeb, CMO